US FDA Explores Pandemic Inspection Alternatives, Post-Pandemic Strategies

26 Mar 2021

Agency's Janet Woodcock and Judy McMeekin say the FDA is looking at options like livestream plant videos while preparing to address backlog after inspections can resume.

The US Food and Drug Administration continues to study additional approaches for drug manufacturing oversight during the COVID-19 pandemic while also preparing for a challenging post-pandemic period, acting commissioner Janet Woodcock and associate commissioner for regulatory affairs Judy McMeekin said in an 18 March “FDA Voices” post.

The agency is studying how to make use of new facility oversight technologies and tools like remote video livestreams of...